drugset / Trial / NCT06882135
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Phase 1
Recruiting
76 enrolled
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HW071021 monotherapy in patients with advanced solid tumors.
Timeline
- Start
- 2025-05-28
- Primary completion
- 2026-09-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HW071021 | Unknown | 50 mg | Oral |